公司资料
Aurinia Pharmaceuticals Inc 股价、新闻与催化剂
- 股票代码:
- AUPH
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Canada
股票表现
15.95 USD (-1.51%)
收盘价
最后更新: 2026年10月1日
1.98B USD
市值
股价为何变动
截至 2026年10月1日，AUPH 下跌 1.51%，收于 $15.95。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune disease, especially kidney-related immune disorders. Its story combines commercial products with the challenge of maintaining growth in a specialty immunology market.
所在地与行业分类
Aurinia is headquartered in Canada and listed on NASDAQ. It sits in specialty biopharma with immunology and renal exposure.
商业模式特征
The company depends on product sales, market access, and the ability to manage a focused franchise in autoimmune disease. Investors watch revenue, label strategy, and pipeline or portfolio updates.
生物医药行业定位
Aurinia occupies a durable specialty-immunology niche within biotech. It has commercial grounding, but the stock remains sensitive to execution and franchise durability.
未来催化剂
- Aurinia’s catalysts are Lupkynis execution, lupus-nephritis adoption, and any label or commercial update that broadens the franchise. The market will care about whether growth stays steady.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。